Muparfostat

Summary

Muparfostat (CHEMBL4297163) is a phase-3 clinical-stage unknown; indicated across 6 conditions including hepatocellular carcinoma and non-small cell lung carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 6 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297163
Name	Muparfostat
Type	Unknown
Max phase	3

Also known as: Muparfostat, PI-88, MUPARFOSTAT

Parent form; salt/anhydrous children: CHEMBL4297162

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
lung neoplasm	2	MONDO:0021117	MONDO:0008903
cutaneous melanoma	1	MONDO:0005012	EFO:0000389
melanoma	1	MONDO:0005105	EFO:0000756

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE2	5
PHASE3	2
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00568308	PHASE3	TERMINATED	Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma
NCT01402908	PHASE3	TERMINATED	A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
NCT00068172	PHASE1/PHASE2	COMPLETED	Study of PI-88 in Patients With Advanced Melanoma
NCT00073892	PHASE1/PHASE2	COMPLETED	PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma
NCT00097851	PHASE2	COMPLETED	Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)
NCT00103389	PHASE2	COMPLETED	Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00130442	PHASE2	COMPLETED	Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
NCT00247728	PHASE2	COMPLETED	PI-88 in Hepatocellular Carcinoma After Hepatectomy
NCT00268593	PHASE2	COMPLETED	Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).